Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite promising product developments and reduced losses, Relmada's high cash burn rate, decreased cash reserves, and looming financial sustainability issues pose significant risks. The Q&A highlights uncertainties in regulatory pathways and market strategies, with potential delays in trials and increased competition. The company's financial situation is precarious, with limited cash to support future R&D activities. Without a clear path to additional financing or significant revenue, the stock is likely to experience negative sentiment, especially in the absence of a market cap to buffer volatility.
Key Financial Performance
Cash, cash equivalents, and short-term investments $20.6 million as of June 30, 2025, compared to $44.9 million as of December 31, 2024. The decrease is attributed to operational expenses.
Cash used in operations $6.4 million for Q2 2025 compared to $13.3 million for Q2 2024, a decrease due to reduced study costs and operational efficiencies.
Research and development expense $2.8 million for Q2 2025 compared to $10.7 million for Q2 2024, a decrease of $7.9 million primarily due to the wind-down of clinical trials for REL-1017, partially offset by increased costs for NDV-01 and sepranolone activities.
General and administrative expense $7.4 million for Q2 2025 compared to $8.1 million for Q2 2024, a decrease of approximately $696,000 due to lower stock-based compensation expense, partially offset by increased employee and consulting service costs.
Net loss $9.9 million for Q2 2025 compared to $17.8 million for Q2 2024, a reduction driven by lower R&D and operational expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
NDV-01 for non-muscle invasive bladder cancer (NMIBC): Demonstrated 91% high-grade disease-free status at any time point in Phase II study. Sustained release formulation of gemcitabine and docetaxel designed to improve bladder exposure, minimize toxicity, and simplify administration. Phase III study planned for 2026.
Sepranolone for compulsivity disorders: Targeting Prader-Willi syndrome (PWS) as first indication. Phase II data in Tourette's syndrome showed proof of concept and good tolerability. Phase II study for PWS planned for 2026.
Bladder cancer market: 85,000 new cases annually in the U.S., with 50% being high-grade disease. NDV-01 aims to address this significant and underserved market.
Compulsivity disorders market: PWS affects 350,000 people globally, including 20,000 in the U.S. Sepranolone aims to address this unmet need.
Financial position: $20.6 million cash balance as of June 30, 2025. Reduced cash usage in operations compared to 2024.
Team expansion: Added two experts in bladder cancer and urologic oncology: Dr. Raj Pruthi as Chief Medical Officer and Dr. Yair Lotan as Chair of Clinical Advisory Board.
Pipeline focus: Prioritizing NDV-01 and sepranolone development. Preparing for Phase III and Phase II studies in 2026.
Regulatory and manufacturing preparation: Plans to interact with FDA and scale up production for clinical batches of NDV-01 and sepranolone.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Cash Burn Rate: The company reported a significant decrease in cash reserves, from $44.9 million at the end of 2024 to $20.6 million as of June 30, 2025. This indicates a high cash burn rate, which could pose a risk to the company's ability to sustain operations and fund its clinical programs without additional financing.
Regulatory and Clinical Development Risks: The company plans to initiate Phase III trials for NDV-01 and Phase II trials for sepranolone in 2026. These trials are subject to regulatory approvals and successful completion of preparatory activities, including FDA interactions and manufacturing scale-up. Any delays or failures in these areas could adversely impact timelines and financials.
Supply Chain and Manufacturing Risks: The company needs to transfer production to a contract manufacturer and complete scale-up for clinical batches of NDV-01 and sepranolone. Any disruptions or delays in the supply chain or manufacturing process could hinder the progress of clinical trials.
Financial Sustainability: The company reported a net loss of $9.9 million for Q2 2025 and a decrease in R&D expenses due to the wind-down of previous trials. However, the ramp-up of new programs will likely increase costs, potentially straining financial resources given the current cash position.
Market and Competitive Risks: NDV-01 and sepranolone target competitive and underserved markets. While the products show promise, they face competition from existing therapies and other companies developing similar treatments. Market acceptance and differentiation will be critical for success.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
NDV-01 Phase III Study: Relmada plans to initiate a Phase III study for NDV-01 in the first half of 2026. Preparations include interactions with the FDA on trial design and transferring production to a contract manufacturer for clinical batch production.
Sepranolone Proof-of-Concept Study: A proof-of-concept study for sepranolone in Prader-Willi syndrome is planned for the first half of 2026. Preparations include FDA interactions on trial design and setting up a product supply chain with contract manufacturers.
Financial Guidance: Relmada is prioritizing the advancement of NDV-01 and expects to align its cash requirements and runway with its clinical and regulatory strategy. The company had $20.6 million in cash as of June 30, 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How do the recent data and UroGen's product approval influence the strategy for NDV-01? Are you focusing on high-grade or moving towards a larger, less competitive market in non-invasive bladder cancer?
A:The strategy considers both opportunities. Low-grade intermediate risk presents a large patient population with recurring tumors and a precedent for approval via single-arm open-label studies, as demonstrated by UroGen. High-grade disease also shows significant efficacy, though it targets a smaller, tougher patient population. Both opportunities align well with NDV-01.
Q:What are you hoping to accomplish in your meeting with the FDA, and what data will you present?
A:The main goal is to discuss whether the UroGen pathway (single-arm, open-label study in chemoablation) is a viable path forward for NDV-01. This will guide the strategy for FDA approval.
Q:Between high-grade data and the opportunity in low to intermediate grade, where do you see more risks, and what would give you confidence to move into low to intermediate grade?
A:The FDA meeting will be crucial in determining the path forward. Low to intermediate grade offers a faster path to FDA approval due to a larger patient population and quicker trial enrollment. However, the risk lies in limited precedent, with only UroGen's study as a reference.
Q:How should we think about R&D expenses going forward, given the recent drop?
A:R&D expenses have decreased because patient enrollment has paused. Current activities include manufacturing and FDA dialogue, which are less costly. Expenses will rise when Phase II and Phase III trials begin next year. The company has sufficient financial resources to support ongoing activities.
Q:Review of Unclear Management Responses
A:Management provided clear answers to all questions, addressing both strategic considerations and financial planning without avoiding any topics.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CR
Chief Medical
Clinical Advisory
Gem Doce
II study
LLC
Maged
Medical Officer
NDV sepranolone
Phase II
Raj
assessment
contract manufacturer
disease status
docetaxel Gem
dysuria
effort month
employee
expert
hematuria
high grade
increase
month Phase
month efficacy
month follow
month point
month study
overview
patient high
preparation plan
progress milestone
rate patient
risk NMIBC
sepranolone result
status month
study patient
study preparation
update sepranolone
RLMD Transcript
Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript
Unknown5-12
The earnings call summary highlights a lack of revenue and increasing net losses, which are negative indicators. The company's operational updates and return plans were not discussed, adding uncertainty. The forward-looking statements emphasize potential risks, and the Q&A section offered no additional clarity. Although the company has sufficient funding until 2029, the increase in R&D and G&A expenses without revenue generation contributes to a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript
Unknown3-19
The earnings call presents a mixed picture: strong financial backing and strategic plans for NDV-01 and sepranolone, but with notable risks in supply chain and financial management. The Q&A section highlights uncertainties, particularly regarding compliance with FDA requirements and market adoption challenges. Despite a positive cash position and reduced R&D expenses, the increase in net loss and operational costs raises concerns. The lack of clear guidance on FDA expectations and market strategy tempers enthusiasm, leading to a neutral stock price prediction.
Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call presents a mixed picture. Financial performance shows reduced losses and expenses, which is positive, but cash reserves are dwindling. Product development updates and strategic plans seem promising, but are contingent on future FDA approvals and trial outcomes, posing significant risks. The Q&A session reveals potential market opportunities but lacks clarity on pricing strategies and timelines. Overall, the sentiment is neutral, as the positive aspects are balanced by uncertainties and risks, particularly in regulatory and market adoption areas.
Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript
Unknown8-8
Despite promising product developments and reduced losses, Relmada's high cash burn rate, decreased cash reserves, and looming financial sustainability issues pose significant risks. The Q&A highlights uncertainties in regulatory pathways and market strategies, with potential delays in trials and increased competition. The company's financial situation is precarious, with limited cash to support future R&D activities. Without a clear path to additional financing or significant revenue, the stock is likely to experience negative sentiment, especially in the absence of a market cap to buffer volatility.
RLMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
